the European Commission (EC). The associated press release 1 stated that several trade associations, representing key industrial sectors, and the EC have agreed on a declaration to establish a voluntary European partnership to implement the Three Rs (reduction, refinement and replacement) concept in relation to animal testing. The press release went on to say that this will be achieved via the establishment of a task force that will initiate and coordinate an action programme to identify barriers to progress, and will propose ways of promoting the development, validation and regulatory acceptance of alternative approaches.
The symposium and the declaration on the Three Rs have been widely trumpeted as being both timely and a significant achievement. While the initiative is indeed very welcome in principle, one wonders what the EC thinks has been going on for the last two decades. Firstly, the EC is responsible for enforcing laboratory animal protection in line with EU Directive 86/609/EEC (currently under revision), which requires reduction and refinement whenever possible, and the use of a replacement alternative method when one is reasonably and practicably available. Secondly, the EC is responsible for legislation that has banned the testing of cosmetics finished products, and also for the application of a recently-introduced 7th Amendment to the EU Cosmetics Directive, 76/768/EEC, that will ban the sale of products that contain ingredients that have been tested on animals. Thirdly, the European Parliament has recently voted on a highly controversial Commission proposal (known as REACH) that has the potential to greatly increase the use of animal testing for new and existing chemicals, as a basis for assessing risk to humans and the environment. I shall return to the above issues later, but I must emphasise that the EC has merely stated that the use of alternatives for testing both cosmetics and chemicals should be maximised, without addressing the way in which this could be achieved. For example, shortly after the EC announced further plans for implementing REACH, we noted that it failed to offer a strategy as to how its requirement for greater use of alternatives should be met, and it even omitted any mention of its own facility, the European Centre for the Validation of Alternative Methods (ECVAM), based at the JRC in Italy. 2 Fortunately, ECVAM was represented at the recent Brussels symposium, and will clearly play a key role in devising a strategy on alternatives.
However, it is precisely due to the implications of these new or impending pieces of legislation, and the longstanding existing regulatory guidelines for animal toxicity testing, that there has been intense lobbying for many years on the part of scientists working on alternatives, as well as animal welfare and protection groups. Such lobbying has been aimed at motivating bodies such as the EC to implement practical measures to ensure that existing and validated alternatives are actually used, and that the development of those that are still needed is facilitated in a targeted and practical manner.
Lobbying takes many forms, but perhaps the most effective is that which has occurred as a result of holding the World Congresses on Alternatives, of which there have been five so far. It was at the third (held in Bologna, and organised by ECVAM with the support of a number of other EC institutions) that the Declaration of Bologna was adopted and signed on 31 August 1999, 3 by many leading experts on animal experimentation and the Three Rs. The declaration stated that: The participants in the 3rd World Congress …….. strongly endorse and reaffirm the principles [of the Three Rs] put forward by Russell and Burch in 1959. Humane science is a prerequisite for good science, and is best achieved in relation to laboratory animal procedures by the vigorous promotion and application of the Three Rs.
If the EC had acted positively on this declaration when it was first proposed, there would already have been some six years of increased focus on developing alternatives, and we would be in a better position to deal with the requirements of the new pieces of EU legislation now before us.
The press release also listed a number of suggested measures for consideration by the task force charged with developing a strategy for the greater implementation of alternatives. These were: a) the mapping of current research activities and strategies; b) promoting cooperation among researchers; c) the development of alternative approaches, including intelligent testing strategies for chemicals; d) facilitating the validation process by using available knowledge; and e) providing practical ATLA 33, 549-552, 2005 549 Editorial "Europe Goes Alternative" -What's All The Fuss About?
mechanisms to facilitate the regulatory acceptance of alternative approaches.
Mapping research activities and current strategies presumably means assessing what is ongoing at the present time. Obviously, this is a sensible and necessary step to avoid unnecessary duplication of effort. Several key databases on alternatives are available, and societies such as the European Society for Toxicology In Vitro (ESTIV) are a source of much useful information. ESTIV undertook such a survey several years ago, and ECVAM is currently engaged in a similar exercise. Also various research strategies, for different toxicity endpoints, have been published in the scientific literature.
The idea of fostering cooperation in research and in the development of alternative approaches deserves to be strongly supported, and FRAME has advocated this on several occasions, most recently in an editorial that made a number of suggestions on alternatives to the UK Government for promotion during its current Presidency of the EU. 4 It is important to realise that the alternatives thus far developed, validated and accepted by regulatory bodies are those for toxicity endpoints whose mechanisms are best understood. Moreover, they are much better for identifying hazard, rather than for characterising and quantifying hazard for risk assessment purposes. The development of further scientifically rigorous in vitro models will very much depend on gaining such understanding, and this will, in turn, depend on progress in basic research. It is therefore vital for there to be greater incentive for fundamental and applied scientists to work together.
At FRAME, we have devoted much time and effort to developing, and commenting on the need for, intelligent testing strategies for REACH, based on exposure, and not merely on hazard identification, for the effective classification and labelling of chemicals, and for improved approaches to risk assessment. 5 We have also criticised schemes which place too much reliance on chemical methods involving in silico ([Q]SAR) modelling and readacross methods, at the expense of in vitro tissue culture techniques, until such time as ways to properly validate in silico approaches have been agreed and implemented, notwithstanding their tremendous potential. 6 We have also developed individual decision-tree and integrated testing strategies for each of the major toxicity endpoints required by REACH. These strategies involve the maximum use of nonanimal methods, but also include in vivo tests where they could still be regarded as essential for enabling a quantitative risk assessment to be undertaken.
Validation (the independent assessment of the relevance and reliability of a test method for a particular purpose) can be achieved in various ways, including conducting dedicated interlaboratory trials with coded test items. Another approach is to use existing data in a weight-of-evidence validation exercise, without the need for a prospective practical validation study. However, we have previously stressed that there are constraints on the flexibility of the validation process, and we have also recently identified a number of criteria that we believe should be applied to weight-of-evidence validation. 7 Despite supporting the principle of trying to find ways of streamlining validation, we strongly caution against measures that will bypass the essential criteria for validation, mentioned earlier, in attempts to satisfy political pressures or commercial interests. 8 Validation studies can take too long, especially when they become unnecessarily complex, as this can confound their effective management. However, there is often a need to develop and validate a series of complementary tests, to enable batteries of assays to be used to model complex toxicological endpoints, such as acute systemic toxicity (being addressed in the very large EU AcuteTox project) and reproductive toxicity (being evaluated in the equally-large EU ReproTect project). Nevertheless, we believe that it is important to ensure that each component test is properly validated in a manageable study, before attempting to validate test batteries as a whole, particularly as the criteria for validating such test batteries still need to be developed and agreed.
The last of the suggested measures for implementing the Three Rs made by the Brussels declaration, relates to facilitating the regulatory acceptance of alternative approaches. This is an issue of great concern, and is crucial to increasing the use of alternatives in testing. Irrespective of whether a test method is validated and has an OECD test guideline written for it, the method will not be used unless it is accepted by regulatory agencies as a replacement for a traditional animal test. At the meeting in Brussels, there was the usual mix of presentations, some exaggerating the capabilities of alternatives, and others cautioning that animal experiments will still be needed for some time to come. What are politicians and laypersons to make of the situation when they hear that, on the one hand, we can replace all animal tests with alternatives, and, on the other hand, that this is currently impossible, without detriment to human well-being and protection of the environment? This problem is exemplified by the fact that a representative of FRAME, when recently giving evidence to a committee investigating the use of non-human primates as laboratory animals, was asked by its members how they could make sense of all the alternatives they had been told about and the wide spectrum of views about their real-world usefulness.
The truth is that, arguing that animal tests should not be used, because they are outdated, because they don't provide useful information, and because they themselves have never been validated, is not necessarily effective and can even be counterproductive. Instead, it is necessary to address the key requirements of regulators, which Robin Fielder, an experienced regulatory toxicologist, indicated some years ago 9 as being the need for a test to be based on a plausible mechanism of toxicity that can be related to an in vivo process, and the need for it to provide information which is at least equivalent to that provided by the respective animal test. Many alternatives have been proposed for various endpoints, several of which certainly fail to meet either of these criteria, and that is why FRAME has recently suggested an invalidation procedure for dealing with such methods. 10 It is therefore a matter of concern that the response to the traditional reluctance of many scientists and regulators to consider implementing alternatives, has often been to over-emphasise the ability of such methods to act as replacements. While this is not always unjustified, it can be detrimental by having the opposite effect of increasing resistance and suspicion. Thus, very shortly following the Brussels symposium, a rather up-beat article, written by the journal's senior European correspondent, appeared in Nature 11 . The appearance of this article is naturally welcome, particularly in such a widely read journal, but, while it mentions several of the issues in an objective way, it portrays a rather simplistic view of the problems involved in developing, and gaining regulatory acceptance of, alternatives. Such a view could well mislead or, worse, antagonise the many readers of Nature who work in fundamental research. In addition, the article focuses on replacement, whereas the Brussels declaration also encompasses the two other Rs of reduction and refinement. We have identified elsewhere that there is much scope for improving the OECD Health Effects Test Guidelines with respect to reduction and refinement. 12 The negative attitude of scientists to alternatives is also illustrated by reactions to proposals for applying entirely non-animal testing strategies to the REACH system. First, there was dismissive criticism of the BUAV's The Way Forward 13 by an EC Scientific Committee. 14 Secondly, several wellknown toxicologists have recently signed a letter 15 to Günther Verheugen (an EU Commissioner), asserting that the "…identification of all relevant hazardous properties and endpoints of adverse effects can only be determined in the intact ani-mal…". In fact, it is noteworthy that, at one stage during the recent discussions on the REACH system, the EU Environment Committee supported many of the arguments proposed by the BUAV in The Way Forward, although they were subsequently rejected by MEPs during a European Parliament hearing. 16 Such negative attitudes toward alternatives need to be taken seriously, since, whether justified or not, they are widely held by those who influence regulatory requirements and legislation. Moreover, as stated earlier, it is true that, currently, there are no accepted ways of using in vitro data for quantitative risk assessment, even though non-animal methods can often provide useful information on mechanisms of toxicity, which are relevant to, but not sufficient for, risk assessment purposes. This is not to say that the current paradigms for risk assessment are not outdated and scientifically inadequate -they certainly are, but the way to achieve change is to approach the problem scientifically, not to make exaggerated claims about alternatives.
Even more importantly, the ability of in vitro test methods to provide definitive evidence of lack of toxicity is severely limited, in the opinion of many, despite the fact that they can often be used for classification and labelling purposes. In order to be able to make a regulatory decision with confidence, based on a negative in vitro result or a series of results, it is necessary to have data from a battery of complementary tests that cover the relevant mechanisms involved in the in vivo toxicity being modelled. Unfortunately, this has not so far been possible in many cases, as we still do not know enough about these mechanisms. For example, soon after the Ames bacterial mutagenicity test was developed in the 1980s, it was thought that this test, together with a few other in vitro tests, would be able to accurately predict carcinogenic potential. However, such hopes were dashed with the discovery of non-genotoxic carcinogens, for which a reliable in vitro testing battery is still not available. Similarly, embryotoxicity involves many potential mechanisms, and the three available in vitro embryotoxicity (teratogenicity) tests have been validated, are useful as screens, but not as definitive and complete replacement tests.
Nevertheless, it is equally true that regulators need to be more open to criticism and to new concepts and suggestions. Take, once again, the examples of carcinogenicity and teratogenicity testing, two endpoints for which there have long been concerns about the relevance of animal data for protecting humans, and for which there have been recent critiques of current testing strategies. For example, in the case of carcinogenicity testing, Andrew Knight and his colleagues compared the IARC and US EPA databases for human carcinogens, and found significant differences in human carcinogenicity classifications for the same chemicals. 17 The IARC classification was more conservative and less reliant on animal data (mainly from rodents). The same authors analysed information on 160 carcinogens in the EPA database, and found wide differences in species, routes of administration and affected target organs. 18 They concluded that such animal bioassay data are unsuitable for characterising human carcinogens. Similarly, the same authors have shown that animal teratogenicity data are unreliable predictors of chemicals that cause birth defects in humans. 19 Yet, although such arguments have been made many times before, regulators persist in asserting that any replacements for such animal tests should accurately predict rodent data, since these are what they have always used for making regulatory decisions! Moreover, a key argument for retaining the rodent bioassay is the need to be able to identify non-genotoxic carcinogens, as stated earlier. Yet, such chemicals are usually specific to one rodent species, one sex and even to one organ, and the significance of such data to human health assessment is therefore highly dubious. This is plainly an absurd situation, particularly when there are in vitro systems that use human cells, which could potentially be used in conjunction with other non-animal approaches to replace the bioassay.
At FRAME, we are often asked why it takes so long to develop and gain acceptance for alternatives. We reply that this task is complex and cannot be rushed, otherwise mistakes could be made which could jeopardise the justified good reputation of those few replacement methods that have thus far been validated and have gained regulatory acceptance, and that are being used by industry and regulatory bodies for making real decisions without the need for laboratory animals.
In conclusion, FRAME urges that the focus should be on a strictly scientific approach to developing alternatives, and that their validation and adoption by regulatory agencies should be facilitated in ways that do not compromise their scientific integrity, and which do not sacrifice the crucial aspects of ensuring that they are demonstrably and independently shown to be truly reliable and relevant for their intended purposes. This is unlikely to be achieved by making false claims about their advantages and capabilities, or by raising false and unattainable expectations in politicians and members of the public.
Until these important scientific issues can be satisfactorily addressed by dialogue and compromise, and separated from commercial and political pressures, the increased use of alternatives for regulatory testing will be seriously impeded. This is why FRAME is organising a scientific workshop on new approaches to risk assessment, at which many of these issues will be discussed.
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